Introduction

The third session in the Perspectives Webinar Series focused on how sB-R extends beyond initial evaluation to actively inform decisions as products move through the lifecycle. While earlier episodes introduced PPV’s framework and operational foundations, Episode 3 explored how the benefit-risk assessment must evolve alongside emerging data and real-world experience.

Led by PPV experts Gita Toyserkani, Gary Bloomgren, and Kieran O’Donnell, the discussion centered on how sB-R enables teams to reassess assumptions, trade-offs, adapt existing risk management strategies, and make more informed data-driven regulatory and clinical decisions over time.

A central theme of the session was that benefit-risk is not a one-time exercise. It is a continuous, iterative process that must be actively managed to remain meaningful and actionable.  

Below is a summary of the core themes and takeaways from the session.

Key Themes: Applying Structured Benefit-Risk Across the Lifecycle

Benefit-Risk Must Be Continuously Reassessed

As products move through development and into postmarketing, new safety, efficacy, and real-world data continuously emerge. sB-R provides a framework to reassess the safety profile in light of the evolving evidence.

However, many organizations still treat benefit-risk as a point-in-time activity rather than an ongoing process. The session emphasized that reassessment is essential to ensure decisions remain aligned with the most current understanding of the data and its use.

Evidence Should Drive Decisions, Not Just Documentation

A key takeaway from the discussion was that data alone does not create value, but rather, how it is used matters. sB-R ensures that new evidence informs real decisions, linking risk, mitigation strategies, and outcomes, including:

• Refining the overall benefit-risk narrative
• Reassessing ongoing commitments such as REMS or PASS
• Modifying or removing risk minimization measures
• Understanding trade-offs
• Updating regulatory strategies

Without this structured approach, data often accumulates without translating into meaningful action.

Proactive Approaches Reduce Organizational Risk

The session highlighted that many teams reassess benefit-risk reactively, triggered by signals, regulatory requirements, or label changes. This reactive model often leads to:

• Continued use of outdated risk controls
• Unnecessary burden on patients and healthcare systems
• Increased operational and financial cost
• Reduced regulatory credibility

A proactive, structured approach shifts benefit-risk from a compliance activity to a value-generating process that supports timely and informed decisions.

Risk Management Strategies that Evolve with the Data

Real-world examples demonstrated that risk mitigation measures introduced early in a product’s lifecycle are not always clinically necessary or commercially viable long-term. As knowledge improves and uncertainty decreases, strategies should be reassessed and adjusted accordingly.

This includes determining whether measures should:

• Continue as designed
• Be modified to reduce burden
• Be removed entirely

Proactive sB-R enables teams to evaluate the incremental value of these measures relative to their impact on patients, providers, and systems.

Structured Benefit-Risk in Practice: Real-World Examples

The session explored several case studies demonstrating how structured reassessment, such as the application of the REMS logic model, informs decision-making:

• Clozapine REMS: A 35-year evolution from strict controls to release following structured reassessment, reduced uncertainty, and improved awareness and adoption by healthcare providers
• Endothelin receptor antagonists (ERA): REMS requirements removed after reevaluation showed labeling alone was sufficient
• CAR-T therapies: REMS released as provider experience and system readiness increased
• Bydureon: Postmarketing evidence recontextualized pancreatitis risk, leading to REMS release
• Tysabri: Risk stratification enabled more personalized, data-driven treatment decisions
• Retinoids: The evaluation of teratogenicity resulted in strengthened risk-minimization measures including Pregnancy Prevention Programmes, additional education programs and SmPC warnings led to these products remaining on the market
• Vioxx: Postmarketing studies showed increased risk of myocardial infarction & stroke with prolonged use, leading to worldwide product recall

Across these examples, a consistent pattern emerged: structured evaluation of evolving evidence enabled more proportionate, effective, and patient-centered decisions.

PPV Perspective: From Evaluation to Action

The session reinforced that sB-R must be designed to support decision-making, not just assessment.

Effective approaches include:

• Demonstrating how benefit-risk thinking evolves over time
• Using all available data, including internal and real-world sources
• Documenting assumptions, uncertainties, and rationale clearly, with clear linkage to risk drivers and mitigation outcomes
• Aligning cross-functional teams around a shared narrative
• Engaging regulators early and consistently

When applied effectively, sB-R becomes a tool for action, enabling teams to make informed, transparent, and defensible decisions throughout the product lifecycle.

Q&A Spotlight: What Teams Wanted to Know

How often should benefit-risk be reassessed?

More frequently than most teams currently practice. Reassessment may be triggered by new data, but should also be embedded as a continuous process rather than a reactive exercise.

Why do organizations struggle to revisit benefit-risk?

Lack of clear ownership, defined triggers, and structured processes often prevents reassessment from happening consistently.

‍How can teams ensure evidence leads to action?

By embedding sB-R into governance and decision-making frameworks, ensuring that new data is evaluated in context and linked to clear outcomes.

‍What is the risk of not reassessing benefit-risk?

Failure to reassess can result in outdated strategies, unnecessary healthcare system and patient burden, increased costs, and reduced ability to justify decisions to regulators.

What’s Next

Webinar 3 builds on PPV’s commitment to advancing sB-R as a practical, lifecycle-driven discipline. This session highlighted the importance of moving beyond static evaluation toward continuous, decision-focused application.

Future sessions in the Perspectives Webinar Series will continue to explore how structured approaches can strengthen real-world decision-making, regulatory alignment, and long-term program success.

Conclusion

Episode 3 demonstrated that sB-R is not just about assessing a product’s profile. It’s about continuously using that assessment to inform benefit-risk decisions.

As evidence evolves, so too must the assumptions, strategies, and actions that define benefit-risk. Organizations that adopt proactive, structured approaches are better positioned to reduce burden, improve outcomes, and maintain regulatory confidence.

Perspective Pharmacovigilance partners with biopharma teams to embed sB-R into real-world decision-making, ensuring that it remains practical, proportionate, and actionable across the full product lifecycle.

Contact us to learn how PPV can help your team move from static assessment to dynamic, decision-driven benefit-risk management.

‍